Main Article Content

Abstract

Background: Lymphoma are group of diseases caused by malignant Lymphocyte that accumulate in lymph nodes and cause the characteristic clinical features of lymphadenopathy. Anaemia is a common feature in lymphoproliferative disease. Hepcidin: is a liver produced acute phase peptide whose overproduction leads to iron limited erythropoiesis. Aim of the study: To assess the level of hepcidin in newly diagnosed lymphoma patients. And correlate it with Hb, stage of disease, bulky disease, and B-symptoms. Patients and methods: Forty patients with newly diagnosed lymphoma were consequently selected from the haematology outpatient clinic at the Medical City24 of them were male and 16 were female. The level of hepcidin was investigated by ELISA technique. Results: The mean age for Lymphoma participants in this research was 43. 6±20. 2 years with range of (14-79) years. M:F ratio was 1. 5:129 patients were anaemic with Hb less than 12g /dL, 21patients had stage IV disease (52. 5%), 7 patients had stage III disease (17. 5%),12 patients had stage II disease (30%). Hepcidin level was significantly increased in lymphoma Patients than control group. There was significant inverse relationship between hepcidin with Hb level. There was significant positive relationship between hepcidin level with the presence of B-symptoms and stage of the disease. Conclusion: Hepcidin level was significantly increased in lymphoma patients compare to healthy control. It was significantly higher in lymphoma patient with anaemia than no anaemic patients. The adverse impact of elevated hepcidin is consistent with demonstration of higher level of hepcidin in patients with B symptoms and advanced stages.

Keywords

hepcidin lymphoma Anaemia

Article Details

How to Cite
Bdaiwi, L. F., Alqasim, A., & Bdaiwi, Y. F. (2024). EVALUATION THE ROLE OF HEPCIDIN IN LYMPHOMA PATIENTS. Central Asian Journal of Medical and Natural Science, 5(1), 421-432. https://doi.org/10.17605/cajmns.v5i1.2345

References

  1. 1. Press, O. W. ; Lichtman, M. A. General Consideration for lymphomas: Epidemiology, etiology, heterogeneity and primary extranodal disease. . In: Kaushansky K, Lichtman MA, Prchal J, et al. Editors. Williams Haematology. Ninth Edition. US:McGraw Hill Professional 2015; 11: 1569.
  2. 2. Lees, C. ; Keane, C. ; Gandhi, M. K. ; Gunawardana,J. Biology and therapy of primary mediastinal B-cell lymphoma: current status and future directions. Br J Haematol. 2019;185(1):25-41.
  3. 3. Metzger, M. L. ; Mauz-Körholz,C. Epidemiology, outcome, targeted agents and immunotherapy in adolescent and young adult non-Hodgkin and Hodgkin lymphoma. Br J Haematol. 2019 Jun;185(6):1142-1157.
  4. 4. Schwock, J. ; Geddie,W. R. Diagnosis of B-cell non-hodgkin lymphomas with small-/intermediate-sized cells in cytopathology. Patholog Res Int. 2012;2012:164934. doi: 10. 1155/2012/164934.
  5. 5. Gunduz,E. ; Celebioglu, M. ; Meltem AKay, O. The role of flow cytometry in the diagnosis of Non-hodgkins lymphoma, Hodgkins lymphoma, granulomatous inflammation and reactive lymph node specimens. JBUON. 2013;18(3):739-45.
  6. 6. Sun, R. ; Medeiros, L. ; Young, K. Diagnostic and predictive biomarkers for lymphoma diagnosis and treatment in the era of precision medicine. Mod Pathol. 2016( 29): 1118–1142 https://doi. org/10. 1038/modpathol. 2016. 92
  7. 7. Paul, T. ; Gautam, U. ; Rajwanshi,A. Flowcytometric immunophenotyping and cell block immunocytochemistry in the diagnosis of primary Non-hodgkins lymphoma by fine-needle aspiration: Experience from a tertiatry care center. Jcytol. 2014 ; 31(3): 123-130.
  8. 8. Mani, H. ; Jaffe, E. S. Hodgkin lymphoma: an update on Its biology with new insights into classification. Clin lymphoma Myeloma. 2009; 9(3): 206-216.
  9. 9. Yasmeen, T. ; Ali, J. ; Khan, K. , Siddiqui, N. Frequency and causes of anemia in Lymphoma patients. Pak J Med Sci. 2019;35(1):61-65. doi: 10. 12669/pjms. 35. 1. 91.
  10. 10. Hong, J. ; Woo, H. S. ; Kim, H. ; et al. Anemia as useful biomarker in Patients with diffuse large B-cell lymphoma treated with R-CHOP immunochemotherapy. Cancer Sci. 2014; 105(12):1569-1575.
  11. 11. Briukhovetska, D. , Dörr, J. , Endres, S. et al. Interleukins in cancer: from biology to therapy. Nat Rev Cancer. 2021( 21): 481–499. https://doi. org/10. 1038/s41568-021-00363-z.
  12. 12. Kim, Y-J; Kim, K-S; Lim, D. , Yang, D. J. ; Park, J-I; Kim, K. W. ; Jeong J-H, Choi H-S, Kim D-K. Epigallocatechin-3-Gallate (EGCG)-Inducible SMILE Inhibits STAT3-Mediated Hepcidin Gene Expression. Antioxidants. 2020; 9(6):514. https://doi. org/10. 3390/antiox9060514.
  13. 13. Kroll, M. H. Hematology. Approach to Internal Medicine. 2015 13:159–202. doi: 10. 1007/978-3-319-11821-5_6. PMCID: PMC7123236. .
  14. 14. Fernandez – Alvarez, R. , Gonzalez – Rodrigues, A. P. , Gonzalez, M. E. Serum ferritin as prognostic marker in classical Hodgkins Lymphoma treated with ABVD-based therapy. leuk lymphoma. 2015
  15. 15. Nemeth, E. , Ganz, T. Hepcidin and Iron in Health and Disease. Annu Rev Med. 2023 27;74:261-277. doi: 10. 1146/annurev-med-043021-032816.
  16. 16. D'Angelo, G. Role of hepcidin in the pathophysiology and diagnosis of anemia. Blood Res. 2013;48(1):10-5. doi: 10. 5045/br. 2013. 48. 1. 10. .
  17. 17. Katsarou, A. , Pantopoulos, K. Hepcidin Therapeutics. Pharmaceuticals (Basel). 2018 21;11(4):127. doi: 10. 3390/ph11040127.
  18. 18. Vela,D. Hepcidin, an emerging and important player in brain iron homeostasis. J Transl Med. 2018 (16) 25. https://doi. org/10. 1186/s12967-018-1399-5
  19. 19. Georgopoulou, U. ; Dimitriadis, A. ,Fako, P. ; et al. Hepcidin and the iron enigma in HCV infection. Virulence. 2014; 5(4): 465-476.
  20. 20. Fadhil, M. S. ; Al-Nueimy, W. M. , Lazim, A. F. Hodgkin’s lymphoma. An immunohistochemical profile in northern Iraq. Saudi Med J. 2014; 35(5): 448-453.
  21. 21. Results of Iraqi Cancer Registry 2009, Iraqi Cancer board, Iraqi Cancer Registry Centre, Ministry of Health, Baghdad-Iraq. 2009. 133-148.
  22. 22. Yaqo, R. T. ; Hughson, M. D. ; Sulayvani, F. K. , et al. Malignant lymphoma in northern Iraq: a retrospective analysis of 270 cases according to the World Health Organization classification. Indian J Cancer. 2011; 48(4):446-451
  23. 23. Alwan, A. F. ; Al-Rahal, N. K. ; Shabeeb, Z. A. , et al. Incidence of Epstein Barr Virus infection in newly diagnosed non-Hodgkin lymphoma in the national center of hematology-single center study. Iraqi Journal of Cancer and Medical Genetics. 2014; 7: 21-25.
  24. 24. Kamil,T. S. ; Al-rawi, R. A. ; Alhaideri M. Immunohistochemical and clinicopathological study of non-Hodgkin's lymphoma in Erbil, Kurdistan. Zanco J Med Sci. 2014; 18(2): 756-762.
  25. 25. Biggar, R. J. ; Jhonnsen, J. S. ; Smedby, K. E. , et al. Serum YKL-40 and IL-6 Levels in Hodgkin Lymphoma. Clin Cancer Res. 2008; 14(21): 6974-6978.
  26. 26. Kurzrock,R. ; Redman, J. ; Cabanillas, F. ; et al. Serum IL-6 Are elevated in lymphoma Patients and correlate with survival in Advanced H. D and with B-symptoms. CANCER RESEARCH. 1993; 53(9): 2118-2122.
  27. 27. Pedersen, L. M. ; Sorensen, P. G. Mediators of inflammation correlate with microalbuminuria in patients with non-hodgkins lymphoma. British Journal of Haematology. 2003; 121:275-279.
  28. 28. Ishtiaq, J. ; Jehanzeb, K. ; Ali,N. ; et al. Bone Marrow Infiltration and Pattern in Previously diagnosed Patient of non-hodgkin lymphoma( a single center study). Pak Armed Forces Med J. 2017; 67 (2): 249-252.
  29. 29. Nadeem, M. ; Nagi, N. ; Hussain, I. ; et al. Frequency of Bone Marrow Involvement in Hodgkin's Lymphoma on First Presentation. Journal of the College of Physicians and Surgeons Pakistan. 2009; 19(12): 766-771.
  30. 30. Al-Karawi, Abdullah Salim, and Ali Saad Kadhim. "Exploring the role of autoantibodies in Iraqi females with polycystic ovary syndrome. "
  31. 31. Ludwig H, Van-Belle S, Barrett-Leep P, et al. The European Cancer Anaemia Survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients. Eur J Cancer. 2004;40(15):2293-2306.
  32. 32. Birgegard,G. Managing anemia in lymphoma and multiple myeloma. The Clin Risk Manag. 2008; 4(2): 527-539.
  33. 33. Guney, N. ; Soydin, H. O. ; Basaran, M. ; et al. Serum levels of interlenkin-6 and interlenkin-10 in Turkish Patient with aggressive, non-Hodgkin's lymphoma. Asian Pac J Cancer Prev. 2009; 10:669-674.
  34. 34. Hara, M. ; Ando, M. ; Tsuchiya, K. ; et al. Serum hepcidin-25 level linked with high mortality in Patients with non-Hodgkin lymphoma. Ann Hematol. 2015; 94: 603-608.
  35. 35. Ibricevic-balic, L. ; Icindic-Nakas, E. ; Hasic, S. ; et al. Dilemma: Correlation Between Serum Level of Hepcidin and IL-6 in Anemic Myeloma Patients. Med Arch. 2016; 70(6): 429–432.
  36. 36. Hassan, E. A. ; Kamal, G. M; Sedky, A. M. ; et al. Role of Hepicidin in multiple myeloma and lymphoma Patients. International Journal of innovative research and development. 2017; 6(6): 181-186.
  37. 37. Alajeeli, F. S. , Al-Karawi, A. S. , & Ali, M. M. (2023). The Immunological Significance of Medicinal Plants in Disease Control and Prevention in Humans. Al-Salam Journal for Medical Science, 2(2), 13-19.
  38. 38. Abid, F. M. , Al-Ajeeli, F. S. , Al-Karawi, A. S. , & Rasool, K. H. (2023). Reversed phase HPLC determination of total homocysteine, cysteine, cysteinyl glycine, glutathione in plasma of epileptic patients. The American Journal of Medical Sciences and Pharmaceutical Research, 5(07), 34-45.